BioElectronics Corporation (OTC: BIEL) released a Chairman's Update from Richard Staelin, PhD, detailing sales growth, cost reduction, and progress on key strategic initiatives. The company reported a small profit for calendar year 2025, driven by disciplined cost control including office relocation and staff reductions.
Revenue-generating initiatives include targeted advertising campaigns aimed at medical professionals and healthcare providers to increase awareness of RecoveryRx, a non-opioid pain management device. Consumer-focused social media advertising targeting Generation X is also underway to boost brand visibility for chronic musculoskeletal pain relief.
The company continues outreach to physician-owned ambulatory surgical centers and orthopedic practices to identify a clinical trial partner for RecoveryRx. The goal is to participate in a postoperative clinical study that could support qualification for reimbursement under the federal NO PAIN Act initiative, which represents a long-term opportunity for broader adoption of non-opioid pain management technologies.
International efforts include working with legal counsel in Singapore and funders in China regarding arbitration proceedings with a former distributor. The company remains committed to protecting its intellectual property and contractual rights.
BioElectronics has moved forward with its strategic distribution and licensing relationship with Electrome Corporation. Initial conditions of the supply agreement have been satisfied, and Electrome has placed an initial purchase order. Manufacturing is underway, and Electrome is planning a commercial launch of BioElectronics' pulsed shortwave therapy products through its platform.
Chairman Staelin stated, 'This new endeavor represents an important operational milestone and provides another potential pathway to increase consumer awareness and access to our FDA-cleared, drug-free pain therapy products.' He emphasized that this relationship is part of a broader strategy including clinical market development, direct professional outreach, consumer education, international opportunities, and protection of intellectual property rights.
The company remains encouraged by growing interest in non-drug pain management solutions and believes it is well positioned in the evolving electroceutical and non-opioid pain management markets.
Forward-looking statements in the release involve risks and uncertainties, and the company undertakes no obligation to update them.
